article thumbnail

Bayer delivers on medical innovation fueling transformation of pharma business

The Pharma Data

Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.

article thumbnail

Bayer expands global clinical program for darolutamide in prostate cancer

The Pharma Data

The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline.

article thumbnail

Meeting public expectations of diagnostics is the next big test for the NHS

pharmaphorum

Estimates of medical diagnostics worth to the UK vary – MedTech Europe puts its value at around £1billion while the Office for Life Sciences reported in 2018 that it accounts for around 27% of the £24 billion turnover generated annually by the UK’s medtech sector.